Neurocrine Biosciences (NBIX) Change in Receivables (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Change in Receivables of $84.3 million for Q2 2026, up 5.77% year-over-year from $79.7 million in Q2 2025, and up 3.56% on a QoQ basis from $81.4 million in Q1 2026.
Neurocrine Biosciences (NBIX) Change in Receivables (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Change in Receivables for 17 years, with the latest figure at $84.3 million in Q2 2026.
- Change in Receivables for Q2 2026 came in at $84.3 million, up 5.77% year-over-year; the trailing twelve-month figure through Jun 2026 was $259.6 million (up 103.61% YoY), and the FY2025 annual result was $210.5 million, up 428.89% from the prior year.
- Change in Receivables improved to $84.3 million in Q2 2026, from $81.4 million in the prior quarter.
- Over five years, Change in Receivables peaked at $132.3 million in Q3 2025 and troughed at -$38.4 million in Q4 2025.
- A 5-year average of $37.1 million and a median of $26.3 million in 2022 frame the typical range for Change in Receivables.
- The widest annual swing landed in 2022, when Change in Receivables surged 938.71%; it then tumbled 1820.0% in 2025.
- A 5-year view of Change in Receivables shows it stood at $46.5 million in 2022, then sank by 53.98% to $21.4 million in 2023, then sank by 109.35% to -$2.0 million in 2024, then tumbled by 1820.0% to -$38.4 million in 2025, then surged by 319.53% to $84.3 million in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were $84.3 million in Q2 2026, $81.4 million in Q1 2026, and -$38.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.09 Bn | 7.43 Bn | 397.90 Mn | 48.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 84.30 Mn |
| Jun 30, 2026 | 84.30 Mn |
| Mar 31, 2026 | 81.40 Mn |
| Mar 31, 2026 | 81.40 Mn |
| Dec 31, 2025 | -38.40 Mn |
| Dec 31, 2025 | -38.40 Mn |
| Sep 30, 2025 | 132.30 Mn |
| Sep 30, 2025 | 132.30 Mn |
| Jun 30, 2025 | 79.70 Mn |
| Jun 30, 2025 | 79.70 Mn |
| Mar 31, 2025 | 36.90 Mn |
| Mar 31, 2025 | 36.90 Mn |
| Dec 31, 2024 | -2.00 Mn |
| Dec 31, 2024 | -2.00 Mn |
| Sep 30, 2024 | 12.90 Mn |
| Sep 30, 2024 | 12.90 Mn |
| Jun 30, 2024 | 17.60 Mn |
| Jun 30, 2024 | 17.60 Mn |
| Mar 31, 2024 | 11.30 Mn |
| Mar 31, 2024 | 11.30 Mn |